Brett P Monia sold $12M of IONS
Chief Executive Officer at IONIS PHARMACEUTICALS INC. 203,814 shares at an average of $60.32, traded Sep 3, 2025, filed Sep 4, 2025.
Score components
- +25RoleCEO
- +25Trade size$12.3M at market
- +20Share of holdings soldSold 72% of holdings
- +15Cluster13 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874015-25-000221, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 3, 2025 | MOption exercise Common Stock | +102,900 | $53.77 | $5.5M | 282,909 | Sep 4, 2025 |
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -16,615 | $59.12 | $982k | 266,294 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Common Stock | +42,030 | $37.58 | $1.6M | 308,324 | Sep 4, 2025 |
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -127,500 | $60.13 | $7.7M | 180,824 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Common Stock | +31,316 | $32.60 | $1.0M | 212,140 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Common Stock | +27,568 | $32.60 | $899k | 239,708 | Sep 4, 2025 |
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -59,699 | $61.06 | $3.6M | 180,009 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -31,316 | $0.00 | $0 | 67,741 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -27,568 | $0.00 | $0 | 40,173 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -42,030 | $0.00 | $0 | 76,643 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -102,900 | $0.00 | $0 | 0 | Sep 4, 2025 |
Related signals
Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | IONIS PHARMACEUTICALS INC | Shannon L. Devers EVP, Chief Human Resources Ofc | $1.4M 16,777 shares | -49% | |
| 20Weak | IONIS PHARMACEUTICALS INC | Brian Birchler EVP, Corp and Development Ops | $609k 8,000 shares | -14% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Brian Birchler EVP, Corp and Development Ops | $1.7M 23,900 shares | -35% | |
| 23Weak | IONIS PHARMACEUTICALS INC | Shannon L. Devers EVP, Chief Human Resources Ofc | $531k 7,263 shares | -33% | |
| 20Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $113k 1,625 shares | -5% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $1.0M 15,000 shares | -32% | |
| 5Weak | IONIS PHARMACEUTICALS INC | Patrick R. O'Neil EVP CLO & General Counsel | $110k 1,700 shares | -3% | |
| 26Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $743k 11,950 shares | -27% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Patrick R. O'Neil EVP CLO & General Counsel | $1.4M 21,000 shares | -27% | |
| 25Weak | IONIS PHARMACEUTICALS INC | C Frank Bennett EVP, Chief Scientific Officer | $358k 6,000 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.